Comparative Single-dose Bioavailability Clinical Study of Different Coenzyme Q10 Products (NCT05272228) | Clinical Trial Compass
CompletedNot Applicable
Comparative Single-dose Bioavailability Clinical Study of Different Coenzyme Q10 Products
Slovenia25 participantsStarted 2022-03-09
Plain-language summary
The randomized, open-label, three period crossover single-dose bioavailability study with three coenzyme Q10 products
Who can participate
Age range40 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* subject informed consent form
* aged between 40 and 55 years old
* body mass for women 65± 5 kg and for men 85± 5 kg
* non-smoking
* healthy, without cardio-vascular diseases, diabetes, neurodegenerative diseases
* absence of any prescribed medication during the study
* willing to avoid a consumption of any food supplements at least 2 weeks before and during the study
* willing to study all study procedures
Exclusion Criteria:
* cardio-vascular diseases,
* diabetes,
* neurodegenerative diseases,
* gastrointestinal disorders
* hypotension
* pregnancy
* breast-feeding
* intake of any prescribed medication within two week of the beginning of the study
* intake of any food supplements within two week of the beginning of the study
* drug or alcohol abuse
What they're measuring
1
Serum coenzyme Q10 concentrations
Timeframe: 0,2,4,6,8,12 and 24 hours after ingestion